It said the FDA has indicated it would grant the new application priority review status.Aciphex, known chemically as rabeprazole sodium, belongs to a class of drugs known as proton pump inhibitors designed to suppress production of stomach acid that can burn and damage the esophagus, a condition known as gastroesophageal reflux disease.